Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.50 and traded as low as $0.40. Elite Pharmaceuticals shares last traded at $0.41, with a volume of 386,022 shares traded.
Elite Pharmaceuticals Trading Down 0.2 %
The business's 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.50. The company has a market cap of $452.99 million, a price-to-earnings ratio of -21.20 and a beta of 0.04. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.27 and a quick ratio of 1.90.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Recommended Stories
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
